Screener
Cytek Biosciences, Inc. CTKB Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$48.1MBeat by $830.3K
EPS-$0.05Beat by $0.04
Revenue estimate$47.3M
EPS estimate-$0.09
“Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business. Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$52.9M
EPS estimate-$0.07
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Cytek Biosciences, Inc. report Q2 2026 earnings?
- Cytek Biosciences, Inc. (CTKB) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Cytek Biosciences, Inc.'s Q2 2026 revenue and EPS?
- Cytek Biosciences, Inc. reported revenue of $48.1M and eps of $-0.05 for Q2 2026.
- Did Cytek Biosciences, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $47.3M by $830.3K. EPS beat the consensus estimate of $-0.09 by $0.04.
- How did Cytek Biosciences, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 5.6% from $45.6M a year earlier.
- Where can I find Cytek Biosciences, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-335212) and the 10-Q periodic report (0001628280-26-053496) directly on SEC EDGAR. The filing index links above go to sec.gov.
